Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACACB | O00763 | 3/20 | 0.38 |
| ▸ | ACACA | Q13085 | 3/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | L3MBTL3 | Q96JM7 | 5/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 5/20 | 0.36 |
| ▸ | EGFR | P00533 | 2/20 | 0.35 |
| ▸ | MBTD1 | Q05BQ5 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.34 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.34 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | CCR5 | P51681 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3279563 | 1.00 | ACACB (0.38) | ACACBACACAGAAALOX12SMN1; SMN2 | |
| SCHEMBL3279286 | 0.96 | L3MBTL3 (0.38) | ACACBACACAGAAALOX12SMN1; SMN2 | |
| SCHEMBL3278543 | 0.92 | GAA (0.41) | ACACBACACAGAAALOX12SMN1; SMN2 | |
| SCHEMBL3282738 | 0.90 | KRAS (0.34) | ACACBACACAALDH1A1KDM4EHRH3 | |
| SCHEMBL3279106 | 0.89 | ITGB3 (0.39) | GAAALOX12SMN1; SMN2L3MBTL3L3MBTL1 | |
| SCHEMBL3284870 | 0.86 | CCR5 (0.41) | ACACBACACAGAAALOX12SMN1; SMN2 | |
| SCHEMBL3285188 | 0.86 | CCR5 (0.41) | ACACBACACAGAAALOX12SMN1; SMN2 | |
| SCHEMBL3285679 | 0.85 | L3MBTL3 (0.39) | L3MBTL3L3MBTL1MBTD1 | |
| SCHEMBL5249986 | 0.83 | CCR3 (0.37) | ACACBACACAGAAALOX12SMN1; SMN2 | |
| SCHEMBL4718312 | 0.83 | CCR5 (0.39) | ACACBACACAGAAALOX12SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070249592-A1 | Use of selected CGRP antagonists in treatment and prevention of hot flushes in prostate cancer patients | RUDOLF KLAUS | 2007-10-25 | — | — | US | claimed |
| EP-1833484-A1 | USE OF CGRP ANTAGONISTS IN TREATMENT AND PREVENTION OF HOT FLUSHES IN PROSTATE CANCER PATIENTS | Boehringer Ingelheim International GmbH (DE) | 2007-09-19 | — | — | EP | claimed |
| WO-2006069754-A9 | USE OF CGRP ANTAGONISTS IN TREATMENT AND PREVENTION OF HOT FLUSHES IN PROSTATE CANCER PATIENTS | BOEHRINGER INGELHEIM INT (DE) | 2007-08-09 | — | — | WO | claimed |
| US-20060154921-A1 | Use of CGRP antagonists in treatment and prevention of hot flushes in prostate cancer patients | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2006-07-13 | — | — | US | claimed |
| WO-2006069754-A1 | USE OF CGRP ANTAGONISTS IN TREATMENT AND PREVENTION OF HOT FLUSHES IN PROSTATE CANCER PATIENTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2006-07-06 | — | — | WO | claimed |
| US-20070249592-A1 | Use of selected CGRP antagonists in treatment and prevention of hot flushes in prostate cancer patients | RUDOLF KLAUS | 2007-10-25 | — | — | US | disclosed |
| US-20070087995-A1 | beta-L-2'-Deoxy-Nucleosides for the Treatment of Hepatitis B | IDENIX PHARMACEUTICALS, INC. (US) | 2007-04-19 | — | — | US | disclosed |
| US-20060154921-A1 | Use of CGRP antagonists in treatment and prevention of hot flushes in prostate cancer patients | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2006-07-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070087995-A1 | beta-L-2'-Deoxy-Nucleosides for the Treatment of Hepatitis B | PNP, DUT, ATIC | ACACB 1185/4885ACACA 2964/4885GAA 881/4885 |
| US-20060154921-A1 | Use of CGRP antagonists in treatment and prevention of hot flushes in prostate cancer patients | CALCA, CALCB, CALCR | ACACB 2927/4885ACACA 2316/4885GAA 2892/4885 |
| US-20070249592-A1 | Use of selected CGRP antagonists in treatment and prevention of hot flushes in prostate cancer patients | CALCA, CALCB, BDKRB2 | ACACB 3022/4885ACACA 2368/4885GAA 3081/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.